Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danielle Carroll

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Academic Radiology|January 10, 2015
Automated breast segmentation of fat and water MR images using dynamic programmingJosé A Rosado-Toro, Tomoe Barr, Jean-Philippe Galons, et al.
The British Journal of Surgery|March 13, 2026
Surgery for interplanetary space missionsRaghav Khanna, Yang Li, Matthew Cook, et al.
Molecular Cancer Therapeutics|July 5, 2021
Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor ImmunityJames Harper, Shannon Burke, Jon Travers, et al.
Scientific Reports|May 27, 2024
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancerAnsh Kapil, Andreas Spitzmüller, Nicolas Brieu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2022
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)Alan L Ho, Marek Dedecjus, Lori J Wirth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
DESTINY-Breast08: a phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancerKomal Jhaveri, Sherene Loi, Erika Hamilton, et al.
JCO Precision Oncology|May 28, 2026
Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric CancerAnsh Kapil, Henrik Failmezger, Yu Fu, et al.
Nature Medicine|May 4, 2021
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Danielle Carroll, Simon Chowdhury, et al.
Molecular Cancer Therapeutics|March 31, 2021
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ InhibitionLarissa S Carnevalli, Molly A Taylor, Matthew King, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>-</sup> Primary Breast CancerJohn F R Robertson, Abigail Evans, Stephan Henschen, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Academic Radiology|January 10, 2015
Automated breast segmentation of fat and water MR images using dynamic programmingJosé A Rosado-Toro, Tomoe Barr, Jean-Philippe Galons, et al.
The British Journal of Surgery|March 13, 2026
Surgery for interplanetary space missionsRaghav Khanna, Yang Li, Matthew Cook, et al.
Molecular Cancer Therapeutics|July 5, 2021
Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor ImmunityJames Harper, Shannon Burke, Jon Travers, et al.
Scientific Reports|May 27, 2024
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancerAnsh Kapil, Andreas Spitzmüller, Nicolas Brieu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2022
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)Alan L Ho, Marek Dedecjus, Lori J Wirth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
DESTINY-Breast08: a phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancerKomal Jhaveri, Sherene Loi, Erika Hamilton, et al.
JCO Precision Oncology|May 28, 2026
Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric CancerAnsh Kapil, Henrik Failmezger, Yu Fu, et al.
Nature Medicine|May 4, 2021
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Danielle Carroll, Simon Chowdhury, et al.
Molecular Cancer Therapeutics|March 31, 2021
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ InhibitionLarissa S Carnevalli, Molly A Taylor, Matthew King, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>-</sup> Primary Breast CancerJohn F R Robertson, Abigail Evans, Stephan Henschen, et al.
Pageof 3